NQO2
Ribosyldihydronicotinamide dehydrogenase [quinone]
Protein Summary
The enzyme apparently serves as a quinone reductase in connection with conjugation reactions of hydroquinones involved in detoxification pathways as well as in biosynthetic processes such as the vitamin K-dependent gamma-carboxylation of glutamate residues in prothrombin synthesis. This gene encodes a member of the thioredoxin family of enzymes. It is a cytosolic and ubiquitously expressed flavoprotein that catalyzes the two-electron reduction of quinone substrates and uses dihydronicotinamide riboside as a reducing coenzyme. Mutations in this gene have been associated with neurodegenerative diseases and several cancers. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Mar 2014]
- ENST00000338130
- ENSP00000337773
- ENSG00000124588
- ENST00000380430
- ENSP00000369795
- ENST00000380455
- ENSP00000369822
- NMOR2
- QR2
- DHQV
- DIA6
- NMOR2
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
interacting protein | 0.86 | ||
histone modification site profile | 0.79 | ||
transcription factor binding site profile | 0.79 | ||
disease perturbation | 0.74 | ||
drug | 0.68 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 114.81 (req: < 5)
Gene RIFs: 42 (req: <= 3)
Antibodies: 473 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 114.81 (req: >= 5)
Gene RIFs: 42 (req: > 3)
Antibodies: 473 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 13
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligands: 167
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drugs: 8